A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2006
10/31/2006	US7129057 Human testis specific serine/threonine kinase 3
10/31/2006	US7128930 Topically administering to the genitals of a patient with sexual dysfunction an ethyl ester of L-arginine, combination of ascorbic acid and ascorbic acid palmitate as antioxidants to cause the desired level of blood flow to erectile tissue while minimizing peroxynitrite levels
10/31/2006	US7128923 Mixture with non-formaldehyde preservative; microbiocides; chemical resistance; drugs, medical equipment, cosmetics; antiaging, wrinkle resistance; skin disorders
10/31/2006	US7128922 Compositions of leukaemia inhibitory factor
10/31/2006	US7128916 Bacteriophage-mediated immunisation
10/31/2006	CA2383599C Methods, kits and compositions for using pyrrole derivatives
10/31/2006	CA2329217C Stable extended release oral dosage composition comprising desloratadine and pseudoephedrine
10/31/2006	CA2302850C Stretch mask with an adhesive matrix that can be extended at least when wet
10/31/2006	CA2281474C Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof
10/31/2006	CA2267160C Antimycotic gel for the treatment and prevention of skin mycoses
10/31/2006	CA2209303C Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
10/26/2006	WO2006113172A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers
10/26/2006	WO2006113033A1 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/26/2006	WO2006112889A1 Dosage forms of risedronate
10/26/2006	WO2006112556A1 Method for treating cancer using premedication
10/26/2006	WO2006112449A1 NOVEL NON-HUMAN ANIMAL MODEL FOR ALZHEIMER'S DISEASE HAVING DETERIORATED A-β EXCRETION FUNCTION
10/26/2006	WO2006111198A1 Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease
10/26/2006	WO2006084694A3 Use of the mcm8 gene for the preparation of a pharmaceutical composition
10/26/2006	WO2006063707A3 Novel pharmaceutical composition containing at least one dolastatin 10 derivative
10/26/2006	WO2005119261A3 Glut5 transporters expressed in cancer cells
10/26/2006	WO2005112633A3 Compounds and compositions for delivering active agents
10/26/2006	WO2005099758A3 Injectable bioartificial tissue matrix
10/26/2006	WO2005070008A8 Polymer no donor predrug nanofiber coating for medical devices and therapy
10/26/2006	WO2002101008A3 Intracellular signaling molecules
10/26/2006	US20060241186 Alkylating agent combinations in the treatment of cancer
10/26/2006	US20060241165 Method and kit for regulation of microvascular tone
10/26/2006	US20060241143 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
10/26/2006	US20060241134 Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
10/26/2006	US20060241131 Pyrrolo[2,3-d]pyrimidine compounds
10/26/2006	US20060241124 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
10/26/2006	US20060241122 Combination therapy for the treatment of neoplasms
10/26/2006	US20060241102 Medicinal compositions
10/26/2006	US20060241059 Treatments for viral infections
10/26/2006	US20060241037 Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
10/26/2006	US20060241021 Methods of treating cognitive dysfunction by modulating brain energy metabolism
10/26/2006	US20060240465 CNG2B: a novel human cyclic nucleotide-gated ion channel
10/26/2006	US20060240417 Agent controlling the apoptosis induction by p73
10/26/2006	US20060240410 Retroviral protease inhibitor combinations
10/26/2006	US20060240128 Combined immediate release and extended release analgesic composition
10/26/2006	US20060240123 Pharmaceutical composition
10/26/2006	US20060240120 Composition for lowering blood glucose
10/26/2006	US20060240119 Pharmacologically active strong acid solutions
10/26/2006	US20060240118 Pharmacologically active strong acid solutions
10/26/2006	US20060240113 Anticancer agents; prevent forming blood vessels; removal blockager
10/26/2006	US20060240103 Effervescent compositions comprising bisphosphonates and methods related thereto
10/26/2006	US20060240075 Carnitine retention
10/26/2006	US20060240056 Treatment of skin with adenosine or adenosine analog
10/26/2006	US20060240037 Methods and compositions for the treatment and prevention of degenerative joint disorders
10/26/2006	US20060240036 I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
10/26/2006	US20060240020 Inhibition of complement activation
10/26/2006	US20060240019 Antagonists of HMG1 for treating inflammatory conditions
10/26/2006	US20060240014 Methods and compounds for the treatment of vascular stenosis
10/26/2006	US20060240011 Use of nf-kappa b inhibitors for the treatment of mastitis
10/26/2006	US20060240004 Methods for treating tweak-related conditions
10/26/2006	US20060240000 Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound
10/26/2006	US20060239991 polypeptide has the biological activity of methionyl tRNA synthetase; for the protection against bacterial infections
10/26/2006	US20060239936 Delivery of anti-migraine compounds through an inhalation route
10/26/2006	US20060239912 Carrier molecules
10/26/2006	US20060237004 Methods for treating trigeminal neuralgia
10/26/2006	US20060237003 Methods for treating headaches
10/26/2006	CA2675652A1 Dosage forms of risedronate
10/26/2006	CA2646257A1 Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
10/26/2006	CA2604842A1 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
10/25/2006	EP1715034A1 Regulatory cell controlling immunological activity of t cell
10/25/2006	EP1714969A2 Immunostimulatory nucleic acid molecules
10/25/2006	EP1714676A2 Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
10/25/2006	EP1714651A1 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
10/25/2006	EP1714648A1 Combination drug
10/25/2006	EP1714643A1 Sustained release preparation
10/25/2006	EP1714640A1 Stabilised external skin treatment composition comprising retinol.
10/25/2006	EP1713542A2 COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR
10/25/2006	EP1713499A1 Methods and compounds for modulating triglyceride and vldl secretion
10/25/2006	EP1713486A1 Combination therapy for dementia,depression and apathy
10/25/2006	EP1713485A2 Treatment of degenerative cartilage conditions in a mammal with glycosidase inhibitors
10/25/2006	EP1713478A1 Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor
10/25/2006	EP1713477A2 Combination of voriconazole and an antifungal cyp2c19 inhibitor
10/25/2006	EP1713473A1 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
10/25/2006	EP1713472A2 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
10/25/2006	EP1713471A2 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
10/25/2006	EP1713470A1 Therapeutic combinations
10/25/2006	EP1713459A2 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
10/25/2006	EP1524971B1 Improved transdermal delivery system
10/25/2006	EP1517909B1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
10/25/2006	EP1509498B1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
10/25/2006	EP1501925A4 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
10/25/2006	EP1490030B1 Nanoparticulate compositions of angiogenesis inhibitors
10/25/2006	EP1409525B1 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
10/25/2006	EP1401416B1 Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
10/25/2006	EP1383511B1 Calcilytic compounds
10/25/2006	EP1359939B1 Composition and method for potentiating drugs
10/25/2006	EP1313476B1 Sgk3 used as diagnostic and therapeutic target
10/25/2006	EP1278522B1 Pde-v inhibitors for treatment of parkinson's disease
10/25/2006	EP1153302B1 Diagnostics and therapeutics for macular degeneration
10/25/2006	EP1109901B1 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF
10/25/2006	EP1097167B1 Neurotrophic growth factor
10/25/2006	EP1079811B1 Biodegradable sustained-release alginate gels
10/25/2006	EP0912086B1 Method of screening for drugs for the treatment of alzheimer's disease
10/25/2006	CN1852738A Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
10/25/2006	CN1852737A Combination of a histone deacetylase inhibitor with a death receptor ligand
10/25/2006	CN1852731A Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

1 ... 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 ... 1151